SpringWorks Therapeutics Inc. in Stamford, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, recently announced that Badreddin Edris, Ph.D., currently chief business officer, has been promoted to chief operating officer, and L. Mary Smith, Ph.D., currently senior vice president of clinical research and development, has been promoted to chief development officer.
In his remarks about the promotions, Saqib Islam, CEO of SpringWorks, said “They both embody SpringWorks core values, continuously looking for opportunities on behalf of the patients we ultimately work for. I look forward to partnering with them and the rest of our experienced leadership team as we advance our 10 clinical development programs for patients with severe rare diseases and cancer.
Edris joined SpringWorks in 2018 as chief business officer to lead the company”™s corporate strategy, business development and intellectual property efforts. Previously he was an investment and operating professional on the private equity team at OrbiMed. Before that Edris was a management consultant at Bain & Company. He received his Ph.D. in genetics from Stanford University.
Smith joined SpringWorks at its inception in 2017 and was a founding member of the management team. Prior to joining SpringWorks, Smith was the executive vice president of Gene Therapy at Bamboo Therapeutics, a wholly owned subsidiary of Pfizer. Previously she was the vice president of product development at United Therapeutics where she was responsible for development programs in oncology, regenerative medicine and virology. She holds a Ph.D. in microbiology/immunology from the University of New Hampshire and received her postdoctoral training at Emory University under a NIH post-doctorate research fellowship.
